Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This Phase 1, dose-escalation, double-blind, multiple ascending dose (MAD) study was designed to assess the safety and tolerability of NRL-1049 compared to placebo in healthy adult participants and to determine the maximum tolerated dose (MTD) and to assess pharmacokinetics (PK) and dose proportionality. Additionally, changes in blood Rho-associated protein kinase (ROCK) activity levels will be explored.
Epistemonikos ID: 11a4a545693c7d9ef3b04d43027e4eed941357f9
First added on: Oct 31, 2026